NO995127D0 - Stabiliserte tibolonblandinger - Google Patents

Stabiliserte tibolonblandinger

Info

Publication number
NO995127D0
NO995127D0 NO995127A NO995127A NO995127D0 NO 995127 D0 NO995127 D0 NO 995127D0 NO 995127 A NO995127 A NO 995127A NO 995127 A NO995127 A NO 995127A NO 995127 D0 NO995127 D0 NO 995127D0
Authority
NO
Norway
Prior art keywords
mixtures
tibolone
dosage unit
stabilized
stabilized tibolone
Prior art date
Application number
NO995127A
Other languages
English (en)
Norwegian (no)
Other versions
NO995127L (no
Inventor
Pieter De Hahn
Adrianus Cornelis Petru Rovers
Theodora Antonia Maria La Hurk
Jocominus Antonius Ma Zwinkels
Ryoichi Morita
Original Assignee
Akzo Nobel Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nobel Nv filed Critical Akzo Nobel Nv
Publication of NO995127D0 publication Critical patent/NO995127D0/no
Publication of NO995127L publication Critical patent/NO995127L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO995127A 1997-04-22 1999-10-21 Stabiliserte tibolonblandinger NO995127L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP97201180 1997-04-22
PCT/EP1998/002361 WO1998047517A1 (en) 1997-04-22 1998-04-20 Stabilized tibolone compositions

Publications (2)

Publication Number Publication Date
NO995127D0 true NO995127D0 (no) 1999-10-21
NO995127L NO995127L (no) 1999-10-21

Family

ID=8228228

Family Applications (1)

Application Number Title Priority Date Filing Date
NO995127A NO995127L (no) 1997-04-22 1999-10-21 Stabiliserte tibolonblandinger

Country Status (26)

Country Link
US (6) US6399594B2 (id)
EP (1) EP0975348B1 (id)
JP (1) JPH10316573A (id)
KR (1) KR100580855B1 (id)
CN (2) CN1494908A (id)
AR (1) AR012480A1 (id)
AT (1) ATE281836T1 (id)
AU (1) AU742037B2 (id)
BR (1) BR9809268A (id)
CA (1) CA2288070A1 (id)
DE (1) DE69827484T2 (id)
DK (1) DK0975348T3 (id)
ES (1) ES2232949T3 (id)
HK (1) HK1023508A1 (id)
HU (1) HUP0001780A3 (id)
ID (1) ID22763A (id)
IL (1) IL123984A (id)
NO (1) NO995127L (id)
NZ (1) NZ338028A (id)
PL (1) PL190227B1 (id)
PT (1) PT975348E (id)
RU (1) RU2207133C2 (id)
TR (1) TR199902530T2 (id)
TW (1) TW570798B (id)
WO (1) WO1998047517A1 (id)
ZA (1) ZA983169B (id)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100432093C (zh) 1998-10-16 2008-11-12 欧加农股份有限公司 包含（7α,17α)-17-羟基-7-甲基-19-去甲-17-孕-5（10）-烯-20-炔-3-酮的高纯度组合物
CN1183904C (zh) * 1999-02-26 2005-01-12 盐野义制药株式会社 改进了服用性的咀嚼型软胶囊剂及其制法
US20040229854A1 (en) * 2000-11-28 2004-11-18 Pieter Haan De Immediate release dosage form for HRT
PT1429802E (pt) * 2001-09-28 2013-01-24 Tntgamble Inc Sistema de entrega para componente biológico
US20070098784A1 (en) 2001-09-28 2007-05-03 Nutraceutix, Inc. Delivery system for biological component
GB0125061D0 (en) * 2001-10-18 2001-12-12 Norton Healthcare Ltd Pharmaceutical composition
TW200418525A (en) * 2002-11-20 2004-10-01 Akzo Nobel Nv Coated pharmaceutical tablets containing Tibolone
CN1324041C (zh) * 2003-04-01 2007-07-04 上海迪赛诺医药科技开发有限公司 替勃龙晶型i的制备方法
ES2312996T3 (es) * 2003-04-29 2009-03-01 N.V. Organon Proceso de solidificacion con antidisolvente.
EP1499278B1 (en) * 2003-05-23 2005-06-01 Akzo Nobel N.V. Immediate-release pharmaceutical dosage form comprising polymorphous tibolone
WO2005105278A2 (en) * 2004-05-05 2005-11-10 Akzo Nobel N.V. Antisolvent emulsion solidification process
WO2005117899A1 (en) * 2004-06-02 2005-12-15 Cipla Limited Pharmaceutical composition comprising tibolone and process for procuding the same
WO2005120517A1 (en) * 2004-06-07 2005-12-22 Strides Arcolab Limited Stable liquid suspension formulation comprising synthetic steroids and process for producing the same
CZ300465B6 (cs) * 2007-07-25 2009-05-27 Zentiva, A. S. Zpusob výroby komprimované farmaceutické formulace s obsahem tibolonu
CN102085193B (zh) * 2009-12-08 2013-11-06 北京以岭生物工程技术有限公司 一种替勃龙口腔崩解片及其制备方法
CN104345098B (zh) * 2013-08-05 2016-04-13 华润紫竹药业有限公司 一种测定替勃龙片剂中抗氧剂含量的方法
PL3452019T3 (pl) 2016-05-04 2021-12-20 Novalon S.A. Zastosowanie alkoholi cukrowych w kompozycjach tybolonu

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4701450A (en) 1984-03-21 1987-10-20 Akzo N.V. Steroids for use as immunomodulators
CH676470A5 (id) * 1988-02-03 1991-01-31 Nestle Sa
IE63051B1 (en) * 1989-03-18 1995-03-22 Akzo Nv Pharmaceutical composition which contains a pharmaceutically suitable carrier and the compound having the structure (7alpha, 17alpha)-17-Hydroxy-7-methyl-19-nor-17-pregn-5(10)-en-20-yn- 3-one
AU671706B2 (en) * 1993-03-05 1996-09-05 Akzo N.V. Use of a Pregnane Derivative
ATE227122T1 (de) 1993-09-03 2002-11-15 Smithkline Beecham Corp Stabilisierte tablettenformulierung
CA2159419C (en) * 1994-10-17 2006-07-04 Pieter De Haan Solid pharmaceutical composition comprising an excipient capable of binding water

Also Published As

Publication number Publication date
HK1023508A1 (en) 2000-09-15
JPH10316573A (ja) 1998-12-02
HUP0001780A2 (hu) 2000-12-28
CN1494908A (zh) 2004-05-12
TR199902530T2 (xx) 2000-05-22
WO1998047517A1 (en) 1998-10-29
DK0975348T3 (da) 2005-03-07
TW570798B (en) 2004-01-11
AR012480A1 (es) 2000-10-18
CN1253503A (zh) 2000-05-17
US6514958B1 (en) 2003-02-04
US20040142031A1 (en) 2004-07-22
HUP0001780A3 (en) 2001-02-28
EP0975348A1 (en) 2000-02-02
PL190227B1 (pl) 2005-11-30
KR20010020163A (ko) 2001-03-15
PT975348E (pt) 2005-01-31
US20040142030A1 (en) 2004-07-22
ID22763A (id) 1999-12-09
EP0975348B1 (en) 2004-11-10
NZ338028A (en) 2001-10-26
BR9809268A (pt) 2000-06-27
ATE281836T1 (de) 2004-11-15
NO995127L (no) 1999-10-21
ZA983169B (en) 1998-10-20
DE69827484D1 (de) 2004-12-16
RU2207133C2 (ru) 2003-06-27
PL336658A1 (en) 2000-07-03
US20010005513A1 (en) 2001-06-28
US20030119801A1 (en) 2003-06-26
CN1146424C (zh) 2004-04-21
DE69827484T2 (de) 2005-03-17
US20040142028A1 (en) 2004-07-22
AU8014698A (en) 1998-11-13
CA2288070A1 (en) 1998-10-29
IL123984A (en) 2004-09-27
KR100580855B1 (ko) 2006-05-17
US6399594B2 (en) 2002-06-04
ES2232949T3 (es) 2005-06-01
AU742037B2 (en) 2001-12-13

Similar Documents

Publication Publication Date Title
NO995127D0 (no) Stabiliserte tibolonblandinger
SE9700135D0 (sv) New formulation
MY118371A (en) Tetrahydrolipstatin containing compositions
ATE240344T1 (de) Nor-pregnane zur induzierung hypothalamischer effekte
ES8402155A1 (es) Un metodo para producir formas posologicas unitarias solidas que al administrarse siguen una pauta de liberacion regular y prolongada.
NZ507566A (en) Formulation of fast-dissolving efavirenz capsules or tablets using super-disintegrants
ATA214289A (de) Cyclosporin enthaltende pharmazeutische zusammensetzung
DE69940557D1 (de) Ein hydrokolloid und einen celluloseether enthaltende tablette mit verzögerter freisetzung
DE69801369T2 (de) Peptidanaloge des lh-rh, ihre verwendungen und die sie enthaltenden pharmazeutischen zusammensetzungen
DE68903605T2 (de) Kautablette.
PL348202A1 (en) Pharmaceutically active composition and dispensing device
CS240991A3 (en) Solid forms for oral administration, said forms containing iphosphamide as active component
DE69318153D1 (de) Antihypercholesterämisch-wirksame verbindungen, pharmazeutische präparate und verwendungen davon
HUP9901021A2 (hu) Famciklovirt nagy koncentrációban tartalmazó gyógyászati tabletták
EP0761209A3 (en) Controlled release formulations of ranitidine
DE69808287D1 (de) Pharmazeutische zusammensetzungen von cinchonin dihydrochlorid
NZ241309A (en) Heterocyclic amido prostaglandin analogues, preparation and pharmaceutical compositions thereof
ATE130190T1 (de) Ein dihydropyridinderivat in nanosolform enthaltendes retard-arzneimittel und seine herstellung.
IT8819541A0 (it) Composizione farmaceutica per somministrazione nasale.
SI0808158T1 (en) Medicament form for the delivery of active substances to wounds
ITRM910038A1 (it) Composizioni farmaceutiche aventi come principio attivo calcitonina da somministrarsi per via intranasale.
GB9017999D0 (en) Device for the administration of pharmacologically active substances
ITRM920551A1 (it) Composizioni farmaceutiche somministrabili per via intranasale contenenti calcitonina quale principio attivo.
ATA31798A (de) Pharmazeutische zusammensetzung enthaltend ciclosporin
GB8905489D0 (en) Pharmaceutical composition comprising 3-(n-piperidino-azino)methylrifamycins as active ingredient